By admin 
CureSearch for Children’s Cancer, a national non-profit foundation dedicated to accelerating the development of new and better treatments for pediatric malignancies, has officially announced the appointment of Osama Alsaleh to its Board of Directors. This strategic addition comes at a pivotal moment for the organization as it seeks to bridge the critical funding gap between laboratory discovery and clinical application. Alsaleh, a recognized leader in healthcare innovation and venture capital, brings an extensive portfolio of experience that spans global health initiatives, technology-driven health equity, and strategic corporate partnerships. His appointment is expected to catalyze CureSearch’s mission by leveraging his deep connections within the venture capital ecosystem and the broader healthcare technology sector to address the systemic underfunding of pediatric oncology research.
A Career Defined by Healthcare Innovation and Strategic Leadership
Osama Alsaleh currently serves as the Head of Partnerships at Plug and Play Health, a division of the world’s most active venture capital firm and a leading global innovation platform. In this capacity, he facilitates high-impact collaborations between startups, established healthcare corporations, and institutional investors. His role involves identifying and scaling disruptive technologies that have the potential to transform patient outcomes on a global scale. By joining the CureSearch board, Alsaleh intends to apply these same principles of rapid innovation and strategic scaling to the field of pediatric cancer, where the pace of drug development has historically lagged behind adult oncology.
Prior to his leadership role at Plug and Play, Alsaleh established a significant track record at Oracle Health and Cerner Corporation. During his tenure at Oracle, he was instrumental in the creation of the company’s health equity team. This initiative was designed to address social determinants of health (SDOH), ensuring that technological advancements in healthcare reach underserved populations and that clinical data reflects the diversity of the global population. His work in health equity aligns with CureSearch’s commitment to ensuring that all children, regardless of socioeconomic background, have access to the latest life-saving therapies.
Alsaleh’s experience also includes substantial involvement in philanthropic capital allocation. As a member of the Oracle Charitable Foundation Clinical Decision Committee, he contributed to the evaluation and distribution of more than $42 million in healthcare grants. This background provides him with a unique perspective on the intersection of charitable giving and clinical efficacy, a dual focus that is central to CureSearch’s operational model.
Navigating the Regulatory and Global Health Landscape
Beyond the private sector, Alsaleh has served as a strategic advisor on several high-level governmental and intergovernmental initiatives. His career path includes collaborations with the World Bank Group and the World Health Organization (WHO), where he focused on sustainable health solutions and the implementation of technology in emerging markets.
Domestically, Alsaleh has contributed his expertise to the U.S. regulatory environment. He has advised on quality reporting measures and collaborated with leaders on Centers for Medicare & Medicaid Services (CMS) initiatives. Notably, his expertise was called upon during the height of the global pandemic, where he served as a contributor to the White House COVID-19 Task Force and collaborated with the U.S. State Department. This high-level regulatory experience is particularly valuable to CureSearch, as the organization navigates the complex FDA approval pathways required to bring new pediatric drugs to market.
The Chronic Underfunding of Pediatric Cancer Research
The appointment of a venture capital expert like Alsaleh highlights a sobering reality in the oncology field: the "Valley of Death" in drug development. While adult cancer research receives billions of dollars in private investment due to the large market size, pediatric cancers are often classified as orphan diseases. Because the patient population is smaller, traditional pharmaceutical companies and venture capitalists often view pediatric drug development as a lower return on investment.
Supporting data illustrates this disparity. According to the National Cancer Institute, while survival rates for some childhood cancers have improved, the development of new drugs specifically for children remains stagnant. Since 1980, fewer than 40 drugs have been FDA-approved for use in children with cancer, compared to hundreds for adults. Furthermore, many children are treated with "off-label" medications—drugs designed for adults that may have long-term toxic effects on a child’s developing body.
Alsaleh addressed this disparity directly upon his appointment. "Throughout my work, I have consistently observed that innovations focused on pediatrics, particularly pediatric oncology, remain significantly underfunded and underrepresented within mainstream venture capital and innovation ecosystems," he stated. He emphasized that his goal is to leverage his network to attract the resources necessary to break this cycle of underfunding.
A Chronology of Strategic Growth for CureSearch
The addition of Alsaleh to the board is part of a broader strategic evolution for CureSearch. Founded in 1986 as the National Childhood Cancer Foundation, the organization has shifted its focus over the decades to meet the changing needs of the research community.
- 1986–2010: Focused largely on supporting the Children’s Oncology Group (COG) and clinical trial infrastructure.
- 2012–Present: Transitioned to a "Venture Philanthropy" model. This approach involves funding translational research—projects that are specifically designed to move out of the lab and into clinical trials.
- 2020–2023: Launched several "Acceleration Initiatives" aimed at overcoming the barriers to pediatric drug development, including the CureSearch Catapult Awards.
- 2024: Appointment of Osama Alsaleh to bridge the gap between non-profit research and the global venture capital community.
This chronology demonstrates a clear trajectory toward becoming a facilitator of commercial-grade innovation within the non-profit sector. By bringing in a board member who understands the mechanics of venture capital, CureSearch is positioning itself to "de-risk" pediatric projects, making them more attractive for eventual adoption by the pharmaceutical industry.
Official Responses and Strategic Implications
Jared Brancazio, Chair of the CureSearch Board of Directors, underscored the value of Alsaleh’s multi-disciplinary background. "Osama brings a unique and highly valuable perspective to CureSearch," Brancazio said. "His ability to connect innovation, investment, and healthcare will help expand our reach and unlock new opportunities to advance critical research for children with cancer."
The strategic implications of this appointment are manifold. First, Alsaleh’s expertise in data and technology is expected to assist CureSearch in utilizing real-world evidence and advanced analytics to streamline research. Second, his experience with the Oracle Charitable Foundation suggests he will play a key role in the governance of CureSearch’s grant-making processes, ensuring that funds are directed toward projects with the highest potential for clinical impact.
Finally, his background in health equity will likely influence how CureSearch approaches the diversity of clinical trial participants. In pediatric oncology, ensuring that trials are accessible to children from all demographic backgrounds is essential for developing treatments that are safe and effective for everyone.
Analysis: The Rise of Venture Philanthropy in Oncology
Alsaleh’s move to the CureSearch board reflects a growing trend in the non-profit world known as "Venture Philanthropy." In this model, non-profits act more like investors than traditional donors. They don’t just give money to researchers; they provide strategic guidance, milestones for progress, and connections to industry partners.
For CureSearch, this means focusing on the "translational" phase of research. Many promising discoveries die in the lab because there is no funding to perform the necessary toxicology and safety studies required to start a clinical trial. By bringing in a partner from Plug and Play Health—an organization built on the concept of accelerating startups—CureSearch is signaling its intent to become an accelerator for pediatric cancer cures.
The impact of this approach could be transformative. If CureSearch can successfully attract even a small fraction of the venture capital currently flowing into adult oncology or general biotech, it could provide the "seed funding" necessary to push multiple new pediatric drugs into the pipeline.
Looking Ahead: A Shared Commitment to Children
As Osama Alsaleh begins his tenure on the board, the focus remains squarely on the children and families affected by cancer. Every year, more than 15,000 children and adolescents in the United States are diagnosed with cancer. While survival rates have reached 80% for some types, for others, such as certain brain tumors or metastatic sarcomas, the prognosis remains grim.
By integrating the speed of the tech sector, the rigor of venture capital, and the mission-driven focus of a non-profit, CureSearch and Alsaleh aim to change those statistics. The organization’s supporters and the broader medical community will be watching closely to see how this infusion of innovation-centric leadership translates into new hope for the youngest cancer patients.
The appointment is effective immediately, and Alsaleh is expected to participate in the upcoming strategic planning sessions as CureSearch outlines its funding priorities for the 2025 fiscal year. His presence on the board serves as a call to action for the tech and investment communities to recognize that the fight against pediatric cancer is not just a moral imperative, but a field ripe for the kind of breakthrough innovation that defines the modern era of medicine.
